SoFi Hong Kong Blog - US_NVO
Carrying Weight Ozempic and Wegovy may help patients lose weight. But the weight they carry in the economy is only increasing. By 2030, some 48 million Americans will have shed a collective hundreds of millions of pounds thanks to these treatments, according to industry analysts. These projections have implications for both patients and the broader…Read more
Gone Appétit Novo Nordisk’s (NVO) weight management medications Ozempic and Wegovy — intended for people struggling with type 2 diabetes and obesity, respectively — have shot to popularity, not least, because celebrities are open about using them. But these weight-loss drugs might not only reduce waistlines; they could reduce bottom lines, too. As demand for…Read more